The stock's fall snapped an eight-day winning streak.

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...

US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to discover and develop an antibody-drug conjugate (ADC) against a solid tumor ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...

Remdesivir treatment reduces the risk for 30-day COVID-19-related hospital readmission among all patients discharged alive from initial hospitalization.

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

Timely remdesivir treatment in immunocompromised patients infected with COVID-19 is associated with improved survival outcomes.

The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis Tuesday said they have entered into an option and license agreement to discover and ...

The growing existence of viral infections is driving the viral sensitizers market.New York, USA, Dec. 03, 2024 (GLOBE ...

The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...